P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971156.02746.02 |
| _version_ | 1797280869026627584 |
|---|---|
| author | Nathalie Johnson David Lavie Peter Borchmann Gareth Gregory Alex F. Herrera Leonard Minuk Vladan Vucinic Philippe Armand Abraham Avigdor Robin Gasiorowski Yair Herishanu Colm Keane John Kuruvilla Rachel Marceau West Pallavi Pillai Patricia Marinello John Timmerman |
| author_facet | Nathalie Johnson David Lavie Peter Borchmann Gareth Gregory Alex F. Herrera Leonard Minuk Vladan Vucinic Philippe Armand Abraham Avigdor Robin Gasiorowski Yair Herishanu Colm Keane John Kuruvilla Rachel Marceau West Pallavi Pillai Patricia Marinello John Timmerman |
| author_sort | Nathalie Johnson |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:47:28Z |
| format | Article |
| id | doaj.art-a8737852cae34698a0c1cb539063a54a |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:47:28Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a8737852cae34698a0c1cb539063a54a2024-03-03T06:25:13ZengWileyHemaSphere2572-92412023-08-017e027460210.1097/01.HS9.0000971156.02746.02202308003-00963P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMANathalie Johnson0David Lavie1Peter Borchmann2Gareth Gregory3Alex F. Herrera4Leonard Minuk5Vladan Vucinic6Philippe Armand7Abraham Avigdor8Robin Gasiorowski9Yair Herishanu10Colm Keane11John Kuruvilla12Rachel Marceau West13Pallavi Pillai14Patricia Marinello15John Timmerman161 Jewish General Hospital, Montréal, Canada2 Hadassah Medical Center, Jerusalem, Israel3 University Hospital Cologne, Cologne, Germany4 School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia5 City of Hope, Duarte, United States6 CancerCare Manitoba and University of Manitoba, Winnipeg, United States7 Leipzig University Medical Center, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, Leipzig, Germany8 Dana-Farber Cancer Institute, Boston, United States9 Chaim Sheba Medical Center, Ramat Gan, Israel10 Concord Hospital, University of Sydney, Concord, Australia11 Sourasky Medical Center, Tel Aviv-Yafo, Israel12 Princess Alexandra Hospital, Brisbane, Australia13 Princess Margaret Cancer Centre, Toronto, Canada14 Merck & Co Inc, Rahway, United States14 Merck & Co Inc, Rahway, United States14 Merck & Co Inc, Rahway, United States15 UCLA Medical Center, Los Angeles, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000971156.02746.02 |
| spellingShingle | Nathalie Johnson David Lavie Peter Borchmann Gareth Gregory Alex F. Herrera Leonard Minuk Vladan Vucinic Philippe Armand Abraham Avigdor Robin Gasiorowski Yair Herishanu Colm Keane John Kuruvilla Rachel Marceau West Pallavi Pillai Patricia Marinello John Timmerman P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA HemaSphere |
| title | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_fullStr | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full_unstemmed | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_short | P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_sort | p1065 updated results from an open label phase 1 2 study of favezelimab in combination with pembrolizumab in patients with anti pd 1 naive relapsed or refractory classical hodgkin lymphoma |
| url | http://journals.lww.com/10.1097/01.HS9.0000971156.02746.02 |
| work_keys_str_mv | AT nathaliejohnson p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT davidlavie p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT peterborchmann p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT garethgregory p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT alexfherrera p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT leonardminuk p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT vladanvucinic p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT philippearmand p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT abrahamavigdor p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT robingasiorowski p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT yairherishanu p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT colmkeane p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT johnkuruvilla p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT rachelmarceauwest p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT pallavipillai p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT patriciamarinello p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma AT johntimmerman p1065updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithantipd1naiverelapsedorrefractoryclassicalhodgkinlymphoma |